Taigen Biopharmaceutica (Taiwan) Insiders
| 4157 Stock | TWD 11.45 0.35 2.97% |
Taigen Biopharmaceutica employs about 23 people. The company is managed by 5 executives with a total tenure of roughly 54 years, averaging almost 10.0 years of service per executive, having 4.6 employees per reported executive. Recap of Taigen Biopharmaceutica's management performance can provide insight into the venture performance.
| , MBA Insider VP Devel |
| ChiHsin King Insider VP Research |
Taigen |
Taigen Biopharmaceutica Management Team Effectiveness
The company has return on total asset (ROA) of (0.1483) % which means that it has lost $0.1483 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.2147) %, meaning that it generated substantial loss on money invested by shareholders. Taigen Biopharmaceutica's management efficiency ratios could be used to measure how well Taigen Biopharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities.Taigen Biopharmaceutica Workforce Comparison
Taigen Biopharmaceuticals Holdings is number one stock in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 57,945. Taigen Biopharmaceutica adds roughly 23.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Taigen Biopharmaceutica Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Taigen Biopharmaceutica Price Series Summation is a cross summation of Taigen Biopharmaceutica price series and its benchmark/peer.
Taigen Biopharmaceutica Notable Stakeholders
A Taigen Biopharmaceutica stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Taigen Biopharmaceutica often face trade-offs trying to please all of them. Taigen Biopharmaceutica's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Taigen Biopharmaceutica's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| ChiHsin King | VP Research | Profile | |
| MingChu Hsu | Founder Director | Profile | |
| KuoLung Huang | CEO, Chairman | Profile | |
| Richard Lu | VP Fin | Profile |
About Taigen Biopharmaceutica Management Performance
The success or failure of an entity such as Taigen Biopharmaceutica often depends on how effective the management is. Taigen Biopharmaceutica management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Taigen management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Taigen management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please note, the imprecision that can be found in Taigen Biopharmaceutica's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Taigen Biopharmaceuticals Holdings. Check Taigen Biopharmaceutica's Beneish M Score to see the likelihood of Taigen Biopharmaceutica's management manipulating its earnings.
Taigen Biopharmaceutica Workforce Analysis
Traditionally, organizations such as Taigen Biopharmaceutica use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Taigen Biopharmaceutica within its industry.Taigen Biopharmaceutica Manpower Efficiency
Return on Taigen Biopharmaceutica Manpower
| Revenue Per Employee | 56.3M | |
| Revenue Per Executive | 258.9M | |
| Net Income Per Employee | 33.7M | |
| Net Income Per Executive | 155.1M |
Additional Tools for Taigen Stock Analysis
When running Taigen Biopharmaceutica's price analysis, check to measure Taigen Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Taigen Biopharmaceutica is operating at the current time. Most of Taigen Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Taigen Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Taigen Biopharmaceutica's price. Additionally, you may evaluate how the addition of Taigen Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.